Virkningsgraden for vaksiner øker 10 gangern


Leveringsplattformen til Pcib kan bli en nøkkelfaktor for effektfulle vaksiner - samarbeid med BIG PHARMA blir verdifullt
HP17
25.03.2020 kl 08:42 3144

Så var den dokumenterte hausingen i gang igjen av PCIB.
Vennligst legg ut link som dokumenterer denne påstanden

Sjekk q3 rapport og podkast fra radforsk

Det er jo nettopp derfor astra er så interessert i et utvidet samarbeid med Pcib

Avklaring om utvidet kommersielt samarbeid med astra før sommeren - jeg vil tro at dette ikke er blitt mindre interessant
HP17
25.03.2020 kl 10:16 2923

Der kom den negative meldingen.

The pandemic has negatively impacted both the opening of new sites and new patient enrolment into the trial, by postponement of site activation dates, and by the changing priorities and physical constraints that are being implemented at the hospitals as a consequence of the pandemic.
PCI Biotech has per date of this announcement not a complete picture of the long-term consequences regarding timelines and costs for the RELEASE study, but short-term delays and increased costs are expected. For the fimaVacc and the fimaNAc programmes the main identified implications are short-term downturn in business development activities.

https://newsweb.oslobors.no/message/499445
Redigert 25.03.2020 kl 10:17 Du må logge inn for å svare

Dette forandrer ikke på vaksineprogrammet - Pcib har mange ben

Dessuten vil en utsettelse være så viktig
heilo888
25.03.2020 kl 10:25 2862







Ja dette var skuffende! Det blir verken rekrutert pasienter eller nye siter innen GG-studien og det ser ikke ut til at det blir noen avtaler innen de andre områdene inntil videre.



HP17
25.03.2020 kl 10:27 2842

Og en forsinkelse blir kostbasert for PCIB, for hver dag som går så løper de faste kostnadene.

Her leser du som fanden leser bibelen - står ikke noe om forsinkelse av andre samarbeidsavtaler
heilo888
25.03.2020 kl 10:45 2793

Jo i høyeste grad:
PCI Biotech has per date of this announcement not a complete picture of the long-term consequences regarding timelines and costs for the RELEASE study, but short-term delays and increased costs are expected. For the fima Vacc and the fima NAc programmes the main identified implications are short-term downturn in business development activities.

Samtalene med astra pågår
heilo888
25.03.2020 kl 11:02 2733

Hvorfor tror du det. Meldingen sier vel at dette er stoppet opp.
Tenker det blir ca. 3 måneders forsinkelse pga. corona-krisen, og muligheter for en avtale etter 1. oktober en eller annen gang.

Ja, en liten forsinkelse er sannsynlig - men også forsterket fokus på verdien av sørlig vaksineprogrammet.
fabian2
25.03.2020 kl 11:05 2712

Taiwan har startet opp....melding i dag...... 24 millioner mennesker der :)

Samme som hele Norden - tilsammen
heilo888
25.03.2020 kl 11:32 2644

Ja positivt med Taiwan, men de har ikke startet opp!
De har fått godkjennelse i landet Taiwan, men nå skal klinikker godkjennes og klargjøres før man starter med screening og inkludering av pasienter.
Tenker FPD i Taiwan om ca.6 mnd. fra nå.
merida1
25.03.2020 kl 12:53 2568

At PciB kom til å få problemer og havne på 20-tallet fortalte merida 1 dere for flere år siden. Men det var å tale for døve ører. Og merida 1 fikk mye dritt slengt mot seg på grunn av dette
Men merida1 vil likevel anbefale dere å kjøpe SoftOx slik at dere får vasket munnen deres og kanskje tjene noen kroner i tillegg

Du verden - hvor får du all denne kunnskapen fra
merida1
25.03.2020 kl 13:40 2473

Vel , dette visste Sokrates 2350 år siden;)

Sokrates var vel mest kjent for å stille spørsmål - ikke svare.... også for 2350 år siden
merida1
25.03.2020 kl 15:14 2347

Ja, bare fortsett med det, så skal merida1 svare :)
Pilote
26.03.2020 kl 09:30 2101

Er dette relatert til Corona situasjonen?

PCI Biotech: US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants
Oslo (Norway), 26 March 2020 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company, today announces that the U.S. Patent and Trademark
Office (USPTO) has informed the company that a new US patent will be granted
early April 2020. The US patent covers the use of fimaVacc in combination with a
new important class of vaccine adjuvants called toll like receptor agonists.

Toll like receptor agonists (TLR agonists) is a diverse class of molecules that
can be used for enhancing immune responses to several types of vaccines. TLR
agonists have similarities to molecules present in various types of infectious
agents, like viruses and bacteria, and can act as adjuvants to alert the immune
system of a possible infection, thereby activating the immune system. The
combination of TLR agonists with PCI Biotech's vaccine technology, fimaVacc, has
been shown to be effective for enhancing cellular immune responses that are
important for the effect both of therapeutic and prophylactic vaccines. The US
patent to be granted in April 2020 gives broad coverage for the combination of
TLR agonists with the fimaVacc technology.

TLR agonists represent a new important class of vaccine adjuvants that are being
developed with many new vaccine candidates. This US patent is therefore
important for PCI Biotech's partnering efforts and it also provides intellectual
property of importance for our ability to potentially generate an internal
future vaccine pipeline, said Per Walday, CEO of PCI Biotech.

As part of PCI Biotech's strategy for applying the PCI technology for
therapeutic cancer vaccines, several global patent applications were filed in
2013 and 2014. Today's announced US patent secure protection until 2035 and this
patent application is still pending in Europe and key Asian markets.

About fimaVacc
This novel vaccine technology applies a unique mode of action, triggered
endosomal release of antigens, to enhance the cytotoxic effect essential for
therapeutic cancer vaccines as well as for several types of vaccines against
viral and parasitic infections. fimaVacc works in synergy with several other
state-of-the-art vaccination technologies, and is especially effective in
combination with some types of TLR agonists. The fimaVacc programme aims to
enhance the cellular immune responses that are important for the therapeutic and
prophylactic effect of vaccines, and the fimaVacc technology has proven
excellent preclinical efficacy with protein- and peptide-based vaccines. The
technology has shown particularly strong CD8 T-cell immune responses, which are
important for therapeutic vaccination, as well as enhanced helper (CD4) T-cell
and antibody responses.

PCI Biotech successfully translated the vaccination technology into humans
through a Phase I study in healthy volunteers that was completed in May 2019.
The study covered more than 90 subjects and established the tolerability of
fimaVacc across a wide range of doses. The immune results provided proof-of-
concept and demonstrates fimaVacc's potential to enhance overall T-cell
responses, by demonstrating improvement of the immunogenicity of vaccines in
healthy volunteers.

Effective induction of cytotoxic T-cells will be critical to realise the huge
potential of therapeutic cancer vaccines, and is also important for vaccination
against some viral and parasitic infections, but vaccines often fail to generate
such responses. Insufficient delivery of vaccine antigens to the appropriate
presentation pathway in the immune cells may be one of the main reasons for weak
cytotoxic T-cell responses. The fimaVacc technology has the potential to
effectively enhance vaccine presentation through these pathways.

Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Leveringsplattformen er interessant for alle vaksiner
fabian2
27.03.2020 kl 07:33 1841

Det helt uvanlige er å melde fra at det kommer en melding.....det har aldri vært gjort før. Det kan likegodt være en melding fra PCIB til AstraZeneca
oljen
27.03.2020 kl 08:02 1745

Dette er svære greier! Anbefaler alle nye investorer i PCIB å lese den siste børsmeldingen om US Patent, og innse hva den innebærer. På Newsweb samt http://pcibiotech.no/ ligger mye bra informasjon om PCI Biotech, Fimavacc og deres arbeid med utvikling av vaksiner.

At selskapet i følge meldingen kan vente å motta et US Patent allerede i begynnelsen av april, dvs allerede om en uke eller to, innebærer at vi trolig kan vente oss en ny børsmelding når endelig US Patent mottas. -Da er det nye investorer som får med seg dette for første gang, og ny himmelferd kan ventes. PCIB skal over 100 kroner i 2020. Jeg har troen på at det vil skje før sommeren.
Sydney
27.03.2020 kl 08:19 1677

Patent er vel og bra. Men til syvende og sist trengs det lenger i kassa. Noe salgbart .. håper det kan komme noe snart .
fabian2
27.03.2020 kl 10:17 1510

Jaja , synes nå hva dere vil , men verden skjønner dette , opp 20% første timen fredag 27.mars-20

Pcib har mange spennende ben - Og nå vi snakker vel egentlig bare om 1/4 del av selskapet firmavacc

Nå de andre benene begynner å røre på seg kommer de til å gå ganske langt
focuss
27.03.2020 kl 10:26 1467

Patent er da aller første steg. Så starter arbeidet med å sjekke om man har et produkt. Så skal det godkjennes. Forøvrig: Hva skal man med en vaksine som virker 10 ganger så sterkt? Snakkes i 2030. Forøvrig så har vel ikke PCIB penger til å utvikle noen vaksine.
Redigert 27.03.2020 kl 10:28 Du må logge inn for å svare
merida1
27.03.2020 kl 10:26 1460

Problemet med vaksiner er ikke å forsterke dem , men å finne rette giftstoff eller bakterie

Hovedfokus er vaksine mot kreft - leveringsplattformen er helt avgjørende

Som investor handler det om evne til å lytte besitte grovt og fint filter, stole mere på ledelsen og ekspertisen enn seg selv.
Stordalen har ett bra motto når han ansetter folk( de skal selvsagt være flinkere enn meg)
Flere flinke debattanter her inne som er verdt å lytte til👍
fabian2
27.03.2020 kl 14:05 1079

merida er tidligere hartvigsen , og han er ikke til å spøke med. Han ser alt som skjer dagen før